CCXI
Churchill Capital Corp XINASDAQNONENONE
Key Statistics
Market Cap
$569.25M
P/E Ratio
—
EPS
—
Beta
—
52W High
$11.00
52W Low
$10.07
50-Day MA
$10.18
200-Day MA
$10.19
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Churchill Capital Corp XI
ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new drugs for inflammatory disorders, autoimmune diseases, and cancer in the United States. The company is headquartered in Mountain View, California.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | — |
| Operating Margin | 0.00% |
| Return on Equity | 0.00% |
| Return on Assets | 0.00% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $-0.26 |
| Price-to-Book | — |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $41.90M |
| Float | $41.40M |
| % Insiders | 1.19% |
| % Institutions | 16.80% |
More NONE Stocks
SOJESouthern Company (The) Series 2DTGDTE Energy Company 2021 Series EDTBDTE Energy Company 2020 SeriesCGABLThe Carlyle Group Inc. 4.625% Subordinated Notes due 2061MGRBAffiliated Managers Group, Inc.NIQNIQ Global Intelligence plcUZDUnited States Cellular CorporatUZFUnited States Cellular CorporatRILYTB. Riley Financial Inc. 6.00% Senior Notes Due 2028HWCPZHancock Whitney Corporation - 6OXLCLOxford Lane Capital Corp. 6.75% Notes due 2031BBBYBed Bath & Beyond, Inc.
Data last updated: 5/5/2026